Opendata, web and dolomites

OrganoPlate Graft SIGNED

Organ-on-a-Chip technology for in vitro grafting and vascularisation of 3D tissues

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OrganoPlate Graft project word cloud

Explore the words cloud of the OrganoPlate Graft project. It provides you a very rough idea of what is the project "OrganoPlate Graft" about.

2020    organs    completely    accurately    employs    vessels    readiness    human    launched    replacement    sme    lacks    ftes    throughput    year    vascularization    blood    unmet    wealth    million    annual    structure    months    safety    first    tissues    problem    grow    post    empower    cycle    therapeutics    50m    toxicity    animal    dutch    revenues    drug    inside    mini    differ    therapeutic    3d    generates    culture    employ    vitro    graft    professionals    solutions    tissue    vivo    commercially    chip    3m    largely    solution    mimetas    vital    projected    party    fte    organ    clinical    add    alternatives    outside    basic    extensive    settings    body    poc    speed    cell    options    manipulation    points    proof    company    vascularized    biology    tumors    lack    organoplate    aiding    functional    complications    gt    unrivalled    experiments    time    2013    depending    founded    exists    models    efficacy    market    2022    monitored    cultivation    profitable    pathology   

Project "OrganoPlate Graft" data sheet

The following table provides information about the project.

Coordinator
MIMETAS BV 

Organization address
address: JH Oortweg 19
city: Leiden
postcode: 2333CH
website: www.mimetas.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 3˙014˙718 €
 EC max contribution 2˙110˙303 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2021-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MIMETAS BV NL (Leiden) coordinator 2˙110˙303.00

Map

 Project objective

PROBLEM – The drug development cycle, from basic research to testing efficacy, toxicity, and safety of new therapeutics, is largely depending on animal models. However animal biology and pathology differ from human biology at crucial points. The sector is aware of the significant complications in their usage, but lacks better alternatives. Highly advanced technology exists for the culture of cell systems, organs, tumors, etc. outside the body (‘in vitro’). However, the existing culture models lack functional blood vessels – a vital structure inside the body (‘in vivo’). There is a great unmet need for better models of human biology, to speed up both basic research on human biology as well as the development of novel, much needed therapeutic solutions. SOLUTION – OrganoPlate Graft involves the development to market readiness of the first high-throughput in vitro culture method for vascularized tissue that is unrivalled by the available in vitro options. An extensive proof of concept (PoC) for this method has been obtained. The new product will be launched within 6-months post-project and, for the first time, allow for the study and manipulation of human tissues with functional human vascularization. COMPANY – Founded in 2013, the Dutch SME MIMETAS was the first party to commercially exploit organ-on-a-chip technology that enables accurately controlled and monitored in vitro cultivation 3D ‘mini-organs’. MIMETAS currently employs > 60 professionals, generates year-on year multi-million revenues, and is projected to be profitable as of 2020. RESULTS – The results of the 2-year OrganoPlate Graft project will empower Users by aiding them to grow tissues with human vascularization in vitro – enabling the replacement of a wealth of animal experiments and the design of completely novel experiments in research, development and clinical settings. OrganoPlate Graft will cost €3M, employ 10 new FTEs, and is projected to add 40 FTE and >€50M annual revenues to MIMETAS by 2022.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORGANOPLATE GRAFT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ORGANOPLATE GRAFT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More  

NextGen-O2k (2019)

Next Generation Instrument for In-Depth Analysis of Mitochondrial Fitness

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More